Accepted at 1:04 a.m. Nov, 01, 2023 by dollajas
Author: God_Have_MRSA
Related Note: 1462122709023 2
Rationale for change

Meglitinides have the same MOA as sulfonylurea (FA 2023 pg 359) so they should also be included here.

Text Text
Extra
- Screen for these in high risk individuals before abdominal CT

- Exogenous insulin use may cause increased insulin levels and normal or decreased C-peptide levels
Lecture Notes
Empty field
Missed Questions
Empty field
Pathoma
Empty field
Boards and Beyond
Empty field
First Aid

Sketchy



Watch Insulin, Sulfonylureas, Meglitinides, GLP-1 Agonists, DPP-4 Inhibitors


Watch Pancreatic Cancer & Islet Cell Tumors
Sketchy 2
Empty field
Sketchy Extra
Empty field
Picmonic
Empty field
Pixorize


Review Sulfonylureas


Physeo
Empty field
Bootcamp
Watch associated Bootcamp video - Pancreas : Insulin Physiology
OME

Additional Resources
Empty field
One by one
Empty field
#PANCE::ENDO::diabetes #AK_Step1_v12::#Physeo::11_Pathology::02_Endocrine_Pathology::06_Endocrine_Pancreas #AK_Step2_v12::#AMBOSS::lh0vVf #AK_Step1_v12::#Pixorize::03_Pharmacology::08_Diabetes_Drugs_(Old)::05_Second-Gen_Sulfonylureas #AK_Step1_v12::#FirstAid::08_Endocrine::04_Pathology::26_Pancreatic_islet_cell_tumors::01_Insulinoma #AK_Original_Decks::Step_1::Zanki_Step_Decks::Zanki_Endocrine::Endocrine_Physiology #AK_Step1_v12::#FirstAid::08_Endocrine::03_Physiology::10_Insulin #AK_Step1_v12::#Pixorize::03_Pharmacology::08_Diabetes_Drugs_(Old)::04_First-Gen_Sulfonylureas #AK_Step1_v12::#UWorld::COMLEX::24766 #AK_Step1_v12::#Costanzo::Endocrine::09_Endocrine_Pancreas #AK_Step1_v12::#B&B::08_Endocrinology::03_Pancreas::01_Endocrine_Pancreas::Extra #AK_Step2_v12::!Shelf::Psych #AK_Step1_v12::^Systems::Endocrine::Physiology #PANCE::EOR::IM #AK_Step1_v12::#SketchyPath::06_Hepatobiliary::03_Pancreatic_Disease::02_Pancreatic_Cancer_&_Islet_Cell_Tumors #AK_Step2_v12::#Resources_by_rotation::Surgery::nbme::form_3 #AK_Step2_v12::#UWorld::Step::20217 #AK_Step1_v12::#UWorld::Step::1655 #AK_Step1_v12::^Other::^HighYield::1-HighYield #AK_Step2_v12::#UWorld::COMLEX::28006 #AK_Step2_v12::#UWorld::Step::2188 #AK_Step1_v12::#Pixorize::03_Pharmacology::07_Diabetes_Drugs_(New)::07_Sulfonylureas #AK_Step2_v12::#UWorld::COMLEX::104627 #AK_Step1_v12::#AMBOSS::2x0TDR #AK_Step2_v12::#B&B::04_Endocrinology::03_Diabetes::05_Diabetes_Treatment::Extra #AK_Step1_v12::#Bootcamp::Endocrinology::07_Pancreas::02_Insulin_Physiology #AK_Step2_v12::#AMBOSS::8P0OgT #AK_Step3_v12::#UWorld::5986 #AK_Step1_v12::#OME::PreClinical::04_Organ_Systems::06_Endocrine::05_Pancreas::01_The_Endocrine_Pancreas #AK_Step1_v12::#AMBOSS::3XaSBQ #AK_Step1_v12::#OME::04_Organ_Systems::06_Endocrine::05_Pancreas::01_The_Endocrine_Pancreas #AK_Step1_v12::#FirstAid::08_Endocrine::03_Physiology::10_Insulin::01_Synthesis::*Synthesis_Secretion #AK_Step1_v12::#SketchyPharm::05_GI_&_Endocrine::02_Diabetes::01_Insulin,_Sulfonylureas,_Meglitinides,_GLP-1_Agonists,_DPP-4_Inhibitors #AK_Step1_v12::#Pixorize::03_Pharmacology::07_Diabetes_Drugs_(New)::08_Meglitinide !AK_UpdateTags::Step1decks::Zanki-Step-Decks::Zanki-Endocrine::Endocrine-Physiology #AK_Step1_v12::#FirstAid::08_Endocrine::04_Pathology::26_Pancreatic_islet_cell_tumors